ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/27/23
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch EventGlobeNewsWire • 01/11/23
ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200PRNewsWire • 01/03/23
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 41st Annual J.P.PRNewsWire • 12/20/22
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")PRNewsWire • 12/13/22